Abbott Laboratories (ABT)
117.26
+1.33
(+1.15%)
USD |
NYSE |
Nov 21, 16:00
117.25
-0.01
(-0.01%)
After-Hours: 20:00
Abbott Laboratories Enterprise Value: 210.81B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 210.81B |
| November 20, 2024 | 208.50B |
| November 19, 2024 | 210.58B |
| November 18, 2024 | 210.98B |
| November 15, 2024 | 208.45B |
| November 14, 2024 | 206.94B |
| November 13, 2024 | 208.17B |
| November 12, 2024 | 209.38B |
| November 11, 2024 | 210.01B |
| November 08, 2024 | 209.64B |
| November 07, 2024 | 207.41B |
| November 06, 2024 | 210.01B |
| November 05, 2024 | 211.62B |
| November 04, 2024 | 211.48B |
| November 01, 2024 | 213.13B |
| October 31, 2024 | 204.06B |
| October 30, 2024 | 205.93B |
| October 29, 2024 | 204.11B |
| October 28, 2024 | 205.27B |
| October 25, 2024 | 205.53B |
| October 24, 2024 | 209.56B |
| October 23, 2024 | 210.37B |
| October 22, 2024 | 208.83B |
| October 21, 2024 | 210.34B |
| October 18, 2024 | 214.50B |
| Date | Value |
|---|---|
| October 17, 2024 | 211.90B |
| October 16, 2024 | 211.78B |
| October 15, 2024 | 208.71B |
| October 14, 2024 | 210.79B |
| October 11, 2024 | 208.83B |
| October 10, 2024 | 207.96B |
| October 09, 2024 | 208.53B |
| October 08, 2024 | 206.24B |
| October 07, 2024 | 204.04B |
| October 04, 2024 | 202.79B |
| October 03, 2024 | 202.08B |
| October 02, 2024 | 204.53B |
| October 01, 2024 | 204.39B |
| September 30, 2024 | 205.17B |
| September 27, 2024 | 203.39B |
| September 26, 2024 | 203.92B |
| September 25, 2024 | 203.71B |
| September 24, 2024 | 204.98B |
| September 23, 2024 | 207.53B |
| September 20, 2024 | 205.60B |
| September 19, 2024 | 206.39B |
| September 18, 2024 | 207.66B |
| September 17, 2024 | 213.31B |
| September 16, 2024 | 212.44B |
| September 13, 2024 | 210.30B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
124.99B
Minimum
Mar 23 2020
259.06B
Maximum
Dec 27 2021
200.04B
Average
199.78B
Median
Sep 28 2020
Enterprise Value Benchmarks
| Boston Scientific Corp | 143.48B |
| Becton Dickinson & Co | 83.11B |
| ResMed Inc | 36.01B |
| Globus Medical Inc | 11.30B |
| Insulet Corp | 18.87B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.646B |
| Revenue (Quarterly) | 10.64B |
| Total Expenses (Quarterly) | 8.776B |
| EPS Diluted (Quarterly) | 0.94 |
| Gross Profit Margin (Quarterly) | 55.83% |
| Profit Margin (Quarterly) | 15.48% |
| Earnings Yield | 2.81% |
| Operating Earnings Yield | 3.26% |
| Normalized Earnings Yield | 2.809 |